Cargando…
24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy
Long term liver fibrosis (LF) changes and their best -monitoring non-invasive markers (NILFM) after effective anti-HCV DAA therapy are little- known. Matrix-metalloproteases (MMPs) and their tissue-inhibitors (TIMPs) are pivotal in liver inflammation repair. Their plasma levels might assess long-ter...
Autores principales: | Pérez-Is, Laura, Collazos, Julio, de la Fuente, Belén, Morano, Luis, Rivas-Carmenado, Maria, Rodriguez, Manuel, Romero-Favela, Adolfo, Fonseca–González, Galilea de Jesús, Melón, Santiago, Valle-Garay, Eulalia, Asensi, Víctor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907337/ https://www.ncbi.nlm.nih.gov/pubmed/35264591 http://dx.doi.org/10.1038/s41598-022-07548-y |
Ejemplares similares
-
The Burgeoning HIV/HCV Syndemic in the Urban Northeast: HCV, HIV, and HIV/HCV Coinfection in an Urban Setting
por: Morano, Jamie P., et al.
Publicado: (2013) -
T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy
por: Auma, Ann W N, et al.
Publicado: (2021) -
Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022) -
Liver Enzyme Alterations in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Langohr, Klaus, et al.
Publicado: (2008) -
Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
por: Zuckerman, Autumn D., et al.
Publicado: (2019)